Uterine Leiomyomata Clinical Trial
Official title:
A Single Dose lead-in PK Followed by a Randomized, Double-blinded, Controlled, Multiple Dose Study of the Selective Progesterone Receptor Modulator Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
A study of 3 doses of Progenta versus placebo versus Lucron Depot for treatment of leiomyomata.
Three doses of Progenta (CDB4124 - 12.5, 25, 50 mg) versus placebo versus Lucron Depot (leuprolide acetate for depot suspension) was initiated in females with symptomatic leiomyomata. A single dose PK visit was conducted only for subjects randomized to the Progenta arm, between screening and visit 1. A second PK assessment was conducted at Visit 3 (one month on drug) to collect steady state data. Treatment period lasted for 3 months. ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00005095 -
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
|
||
| Completed |
NCT00837161 -
Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids
|
Phase 1/Phase 2 | |
| Completed |
NCT01463462 -
Electronic Catheter Stethoscope
|
N/A |